Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 97 entries
Sorted by: Best Match Show Resources per page
Antiphospholipid-related chorea.

Frontiers in neurology

Peluso S, Antenora A, De Rosa A, Roca A, Maddaluno G, Brescia Morra V, De Michele G.
PMID: 23097646
Front Neurol. 2012 Oct 22;3:150. doi: 10.3389/fneur.2012.00150. eCollection 2012.

Chorea is a movement disorder which may be associated with immunologic diseases, in particular in the presence of antiphospholipid antibodies (aPL). Choreic movements have been linked to the isolated presence of plasmatic aPL, or to primary, or secondary antiphospholipid...

Cite
Peluso S, Antenora A, De Rosa A, et al. Antiphospholipid-related chorea. Front Neurol. 2012;3:150doi: 10.3389/fneur.2012.00150.
Peluso, S., Antenora, A., De Rosa, A., Roca, A., Maddaluno, G., Brescia Morra, V., & De Michele, G. (2012). Antiphospholipid-related chorea. Frontiers in neurology, 3150. https://doi.org/10.3389/fneur.2012.00150
Peluso, Silvio, et al. "Antiphospholipid-related chorea." Frontiers in neurology vol. 3 (2012): 150. doi: https://doi.org/10.3389/fneur.2012.00150
Peluso S, Antenora A, De Rosa A, Roca A, Maddaluno G, Brescia Morra V, De Michele G. Antiphospholipid-related chorea. Front Neurol. 2012 Oct 22;3:150. doi: 10.3389/fneur.2012.00150. eCollection 2012. PMID: 23097646; PMCID: PMC3477765.
Copy Download .nbib Format: NLM
The Multiple Faces of Spinocerebellar Ataxia type 2.

Annals of clinical and translational neurology

Antenora A, Rinaldi C, Roca A, Pane C, Lieto M, Saccà F, Peluso S, De Michele G, Filla A.
PMID: 28904990
Ann Clin Transl Neurol. 2017 Aug 10;4(9):687-695. doi: 10.1002/acn3.437. eCollection 2017 Sep.

Spinocerebellar ataxia type 2 (SCA2) is among the most common forms of autosomal dominant ataxias, accounting for 15% of the total families. Occurrence is higher in specific populations such as the Cuban and Southern Italian. The disease is caused...

Cite
Antenora A, Rinaldi C, Roca A, et al. The Multiple Faces of Spinocerebellar Ataxia type 2. Ann Clin Transl Neurol. 2017;4(9):687-695doi: 10.1002/acn3.437.
Antenora, A., Rinaldi, C., Roca, A., Pane, C., Lieto, M., Saccà, F., Peluso, S., De Michele, G., & Filla, A. (2017). The Multiple Faces of Spinocerebellar Ataxia type 2. Annals of clinical and translational neurology, 4(9), 687-695. https://doi.org/10.1002/acn3.437
Antenora, Antonella, et al. "The Multiple Faces of Spinocerebellar Ataxia type 2." Annals of clinical and translational neurology vol. 4,9 (2017): 687-695. doi: https://doi.org/10.1002/acn3.437
Antenora A, Rinaldi C, Roca A, Pane C, Lieto M, Saccà F, Peluso S, De Michele G, Filla A. The Multiple Faces of Spinocerebellar Ataxia type 2. Ann Clin Transl Neurol. 2017 Aug 10;4(9):687-695. doi: 10.1002/acn3.437. eCollection 2017 Sep. PMID: 28904990; PMCID: PMC5590519.
Copy Download .nbib Format: NLM
Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders.

AIDS research and treatment

Giancola ML, Lorenzini P, Cingolani A, Baldini F, Bossolasco S, Bini T, Monno L, Picchi G, d'Arminio Monforte A, Cinque P, Tozzi V, Antinori A.
PMID: 22957220
AIDS Res Treat. 2012;2012:708456. doi: 10.1155/2012/708456. Epub 2012 Aug 26.

The aim of the present study was to analyse the effect of antiretroviral (ARV) therapy and single antiretroviral drugs on cerebrospinal fluid (CSF) HIV-RNA burden in HIV-infected patients affected by neurological disorders enrolled in a multicentric Italian cohort. ARVs...

Cite
Giancola ML, Lorenzini P, Cingolani A, et al. Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS Res Treat. 2012;2012:708456doi: 10.1155/2012/708456.
Giancola, M. L., Lorenzini, P., Cingolani, A., Baldini, F., Bossolasco, S., Bini, T., Monno, L., Picchi, G., d'Arminio Monforte, A., Cinque, P., Tozzi, V., & Antinori, A. (2012). Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS research and treatment, 2012708456. https://doi.org/10.1155/2012/708456
Giancola, Maria Letizia, et al. "Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders." AIDS research and treatment vol. 2012 (2012): 708456. doi: https://doi.org/10.1155/2012/708456
Giancola ML, Lorenzini P, Cingolani A, Baldini F, Bossolasco S, Bini T, Monno L, Picchi G, d'Arminio Monforte A, Cinque P, Tozzi V, Antinori A. Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS Res Treat. 2012;2012:708456. doi: 10.1155/2012/708456. Epub 2012 Aug 26. PMID: 22957220; PMCID: PMC3432519.
Copy Download .nbib Format: NLM
Impact of Edge Groups on the Hydration and Aggregation Properties of Graphene Oxide.

The journal of physical chemistry. B

Paulista Neto AJ, Fileti EE.
PMID: 29462561
J Phys Chem B. 2018 Mar 08;122(9):2578-2586. doi: 10.1021/acs.jpcb.8b00311. Epub 2018 Feb 26.

Molecular dynamics simulations were used to describe and quantify the role of edge groups on the hydrating properties of graphene oxide (GO). For this, six different oxygen concentrations were investigated, and in four of them, carboxyl groups were present....

Cite
Paulista Neto AJ, Fileti EE. Impact of Edge Groups on the Hydration and Aggregation Properties of Graphene Oxide. J Phys Chem B. 2018;122(9):2578-2586doi: 10.1021/acs.jpcb.8b00311.
Paulista Neto, A. J., & Fileti, E. E. (2018). Impact of Edge Groups on the Hydration and Aggregation Properties of Graphene Oxide. The journal of physical chemistry. B, 122(9), 2578-2586. https://doi.org/10.1021/acs.jpcb.8b00311
Paulista Neto, Antenor J, and Fileti, Eudes E. "Impact of Edge Groups on the Hydration and Aggregation Properties of Graphene Oxide." The journal of physical chemistry. B vol. 122,9 (2018): 2578-2586. doi: https://doi.org/10.1021/acs.jpcb.8b00311
Paulista Neto AJ, Fileti EE. Impact of Edge Groups on the Hydration and Aggregation Properties of Graphene Oxide. J Phys Chem B. 2018 Mar 08;122(9):2578-2586. doi: 10.1021/acs.jpcb.8b00311. Epub 2018 Feb 26. PMID: 29462561.
Copy Download .nbib Format: NLM
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.

Therapeutics and clinical risk management

Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D.
PMID: 28721059
Ther Clin Risk Manag. 2017 Jun 29;13:787-797. doi: 10.2147/TCRM.S135972. eCollection 2017.

BACKGROUND: In January 2014, the European Medicines Agency issued a marketing authorization for dolutegravir (DTG), a second-generation integrase strand transfer inhibitor for HIV treatment. The study aimed at determining the incremental cost-effectiveness ratio (ICER) of the use of DTG+backbone...

Cite
Restelli U, Rizzardini G, Antinori A, et al. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients. Ther Clin Risk Manag. 2017;13:787-797doi: 10.2147/TCRM.S135972.
Restelli, U., Rizzardini, G., Antinori, A., Lazzarin, A., Bonfanti, M., Bonfanti, P., & Croce, D. (2017). Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients. Therapeutics and clinical risk management, 13787-797. https://doi.org/10.2147/TCRM.S135972
Restelli, Umberto, et al. "Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients." Therapeutics and clinical risk management vol. 13 (2017): 787-797. doi: https://doi.org/10.2147/TCRM.S135972
Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients. Ther Clin Risk Manag. 2017 Jun 29;13:787-797. doi: 10.2147/TCRM.S135972. eCollection 2017. PMID: 28721059; PMCID: PMC5499774.
Copy Download .nbib Format: NLM
Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study.

Frontiers in neurology

D'Amore A, Tessa A, Casali C, Dotti MT, Filla A, Silvestri G, Antenora A, Astrea G, Barghigiani M, Battini R, Battisti C, Bruno I, Cereda C, Dato C, Di Iorio G, Donadio V, Felicori M, Fini N, Fiorillo C, Gallone S, Gemignani F, Gigli GL, Graziano C, Guerrini R, Gurrieri F, Kariminejad A, Lieto M, Marques LourenḈo C, Malandrini A, Mandich P, Marcotulli C, Mari F, Massacesi L, Melone MAB, Mignarri A, Milone R, Musumeci O, Pegoraro E, Perna A, Petrucci A, Pini A, Pochiero F, Pons MR, Ricca I, Rossi S, Seri M, Stanzial F, Tinelli F, Toscano A, Valente M, Federico A, Rubegni A, Santorelli FM.
PMID: 30564185
Front Neurol. 2018 Dec 04;9:981. doi: 10.3389/fneur.2018.00981. eCollection 2018.

Hereditary spastic paraplegia (HSP) refers to a group of genetically heterogeneous neurodegenerative motor neuron disorders characterized by progressive age-dependent loss of corticospinal motor tract function, lower limb spasticity, and weakness. Recent clinical use of next generation sequencing (NGS) methodologies...

Cite
D'Amore A, Tessa A, Casali C, et al. Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. Front Neurol. 2018;9:981doi: 10.3389/fneur.2018.00981.
D'Amore, A., Tessa, A., Casali, C., Dotti, M. T., Filla, A., Silvestri, G., Antenora, A., Astrea, G., Barghigiani, M., Battini, R., Battisti, C., Bruno, I., Cereda, C., Dato, C., Di Iorio, G., Donadio, V., Felicori, M., Fini, N., Fiorillo, C., Gallone, S., Gemignani, F., Gigli, G. L., Graziano, C., Guerrini, R., Gurrieri, F., Kariminejad, A., Lieto, M., Marques LourenḈo, C., Malandrini, A., Mandich, P., Marcotulli, C., Mari, F., Massacesi, L., Melone, M. A. B., Mignarri, A., Milone, R., Musumeci, O., Pegoraro, E., Perna, A., Petrucci, A., Pini, A., Pochiero, F., Pons, M. R., Ricca, I., Rossi, S., Seri, M., Stanzial, F., Tinelli, F., Toscano, A., Valente, M., Federico, A., Rubegni, A., & Santorelli, F. M. (2018). Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. Frontiers in neurology, 9981. https://doi.org/10.3389/fneur.2018.00981
D'Amore, Angelica, et al. "Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study." Frontiers in neurology vol. 9 (2018): 981. doi: https://doi.org/10.3389/fneur.2018.00981
D'Amore A, Tessa A, Casali C, Dotti MT, Filla A, Silvestri G, Antenora A, Astrea G, Barghigiani M, Battini R, Battisti C, Bruno I, Cereda C, Dato C, Di Iorio G, Donadio V, Felicori M, Fini N, Fiorillo C, Gallone S, Gemignani F, Gigli GL, Graziano C, Guerrini R, Gurrieri F, Kariminejad A, Lieto M, Marques LourenḈo C, Malandrini A, Mandich P, Marcotulli C, Mari F, Massacesi L, Melone MAB, Mignarri A, Milone R, Musumeci O, Pegoraro E, Perna A, Petrucci A, Pini A, Pochiero F, Pons MR, Ricca I, Rossi S, Seri M, Stanzial F, Tinelli F, Toscano A, Valente M, Federico A, Rubegni A, Santorelli FM. Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. Front Neurol. 2018 Dec 04;9:981. doi: 10.3389/fneur.2018.00981. eCollection 2018. PMID: 30564185; PMCID: PMC6289125.
Copy Download .nbib Format: NLM
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice.

HIV medicine

Armenia D, Bouba Y, Gagliardini R, Fabeni L, Borghi V, Berno G, Vergori A, Cicalini S, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM.
PMID: 33480094
HIV Med. 2021 Jul;22(6):519-525. doi: 10.1111/hiv.13062. Epub 2021 Jan 21.

OBJECTIVES: We evaluated the virological response and resistance profile in combined antiretroviral therapy (cART)-experienced HIV-1-infected patients starting a dual therapy with dolutegravir (DTG) and boosted darunavir (bDRV) for the first time.METHODS: Survival analyses were used to evaluate virological success...

Cite
Armenia D, Bouba Y, Gagliardini R, et al. Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. HIV Med. 2021;22(6):519-525doi: 10.1111/hiv.13062.
Armenia, D., Bouba, Y., Gagliardini, R., Fabeni, L., Borghi, V., Berno, G., Vergori, A., Cicalini, S., Mussini, C., Antinori, A., Ceccherini-Silberstein, F., Perno, C. F., & Santoro, M. M. (2021). Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. HIV medicine, 22(6), 519-525. https://doi.org/10.1111/hiv.13062
Armenia, Daniele, et al. "Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice." HIV medicine vol. 22,6 (2021): 519-525. doi: https://doi.org/10.1111/hiv.13062
Armenia D, Bouba Y, Gagliardini R, Fabeni L, Borghi V, Berno G, Vergori A, Cicalini S, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM. Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. HIV Med. 2021 Jul;22(6):519-525. doi: 10.1111/hiv.13062. Epub 2021 Jan 21. PMID: 33480094.
Copy Download .nbib Format: NLM
Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Ulfhammer G, Edén A, Antinori A, Brew BJ, Calcagno A, Cinque P, De Zan V, Hagberg L, Lin A, Nilsson S, Oprea C, Pinnetti C, Spudich S, Trunfio M, Winston A, Price RW, Gisslén M.
PMID: 34747481
Clin Infect Dis. 2021 Nov 08; doi: 10.1093/cid/ciab943. Epub 2021 Nov 08.

BACKGROUND: The aim of this large multicenter study was to determine variations in cerebrospinal fluid (CSF) HIV-RNA in different phases of untreated HIV-1 infection and its associations with plasma HIV-RNA and other biomarkers.METHODS: Treatment naïve adults with available CSF...

Cite
Ulfhammer G, Edén A, Antinori A, et al. Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study. Clin Infect Dis. 2021;doi: 10.1093/cid/ciab943.
Ulfhammer, G., Edén, A., Antinori, A., Brew, B. J., Calcagno, A., Cinque, P., De Zan, V., Hagberg, L., Lin, A., Nilsson, S., Oprea, C., Pinnetti, C., Spudich, S., Trunfio, M., Winston, A., Price, R. W., & Gisslén, M. (2021). Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . https://doi.org/10.1093/cid/ciab943
Ulfhammer, Gustaf, et al. "Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. (2021). doi: https://doi.org/10.1093/cid/ciab943
Ulfhammer G, Edén A, Antinori A, Brew BJ, Calcagno A, Cinque P, De Zan V, Hagberg L, Lin A, Nilsson S, Oprea C, Pinnetti C, Spudich S, Trunfio M, Winston A, Price RW, Gisslén M. Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study. Clin Infect Dis. 2021 Nov 08; doi: 10.1093/cid/ciab943. Epub 2021 Nov 08. PMID: 34747481.
Copy Download .nbib Format: NLM
Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV.

The Journal of antimicrobial chemotherapy

Tempestilli M, D'Avolio A, De Nicolò A, Agrati C, Antinori A, Cicalini S.
PMID: 34450632
J Antimicrob Chemother. 2021 Nov 12;76(12):3320-3322. doi: 10.1093/jac/dkab319.

No abstract available.

Cite
Tempestilli M, D'Avolio A, De Nicolò A, et al. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. J Antimicrob Chemother. 2021;76(12):3320-3322doi: 10.1093/jac/dkab319.
Tempestilli, M., D'Avolio, A., De Nicolò, A., Agrati, C., Antinori, A., & Cicalini, S. (2021). Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. The Journal of antimicrobial chemotherapy, 76(12), 3320-3322. https://doi.org/10.1093/jac/dkab319
Tempestilli, Massimo, et al. "Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV." The Journal of antimicrobial chemotherapy vol. 76,12 (2021): 3320-3322. doi: https://doi.org/10.1093/jac/dkab319
Tempestilli M, D'Avolio A, De Nicolò A, Agrati C, Antinori A, Cicalini S. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. J Antimicrob Chemother. 2021 Nov 12;76(12):3320-3322. doi: 10.1093/jac/dkab319. PMID: 34450632.
Copy Download .nbib Format: NLM
National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management.

Infectious disease reports

Nicastri E, Petrosillo N, Ascoli Bartoli T, Lepore L, Mondi A, Palmieri F, D'Offizi G, Marchioni L, Murachelli S, Ippolito G, Antinori A.
PMID: 32218915
Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543. eCollection 2020 Feb 25.

On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March...

Cite
Nicastri E, Petrosillo N, Ascoli Bartoli T, et al. National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020;12(1):8543doi: 10.4081/idr.2020.8543.
Nicastri, E., Petrosillo, N., Ascoli Bartoli, T., Lepore, L., Mondi, A., Palmieri, F., D'Offizi, G., Marchioni, L., Murachelli, S., Ippolito, G., & Antinori, A. (2020). National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management. Infectious disease reports, 12(1), 8543. https://doi.org/10.4081/idr.2020.8543
Nicastri, Emanuele, et al. "National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management." Infectious disease reports vol. 12,1 (2020): 8543. doi: https://doi.org/10.4081/idr.2020.8543
Nicastri E, Petrosillo N, Ascoli Bartoli T, Lepore L, Mondi A, Palmieri F, D'Offizi G, Marchioni L, Murachelli S, Ippolito G, Antinori A. National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543. eCollection 2020 Feb 25. PMID: 32218915; PMCID: PMC7097833.
Copy Download .nbib Format: NLM
First-episode psychosis in the Ferrara Mental Health Department: Incidence and clinical course within the first 2 years.

Early intervention in psychiatry

Belvederi Murri M, Bertelli R, Carozza P, Berardi L, Cantarelli L, Croce E, Antenora F, Curtarello EMA, Simonelli G, Recla E, Girotto B, Grassi L.
PMID: 33264815
Early Interv Psychiatry. 2021 Dec;15(6):1738-1748. doi: 10.1111/eip.13095. Epub 2020 Dec 02.

AIM: To examine the incidence of with first-episode psychosis (FEP) in the Integrated Department of Mental Health and Pathological Addictions in Ferrara, Italy, and to examine the association between the Duration of Untreated Psychosis (DUP) and the clinical course.METHODS:...

Cite
Belvederi Murri M, Bertelli R, Carozza P, et al. First-episode psychosis in the Ferrara Mental Health Department: Incidence and clinical course within the first 2 years. Early Interv Psychiatry. 2020;15(6):1738-1748doi: 10.1111/eip.13095.
Belvederi Murri, M., Bertelli, R., Carozza, P., Berardi, L., Cantarelli, L., Croce, E., Antenora, F., Curtarello, E. M. A., Simonelli, G., Recla, E., Girotto, B., Grassi, L. (2021). First-episode psychosis in the Ferrara Mental Health Department: Incidence and clinical course within the first 2 years. Early intervention in psychiatry, 15(6), 1738-1748. https://doi.org/10.1111/eip.13095
Belvederi Murri, Martino, et al. "First-episode psychosis in the Ferrara Mental Health Department: Incidence and clinical course within the first 2 years." Early intervention in psychiatry vol. 15,6 (2021): 1738-1748. doi: https://doi.org/10.1111/eip.13095
Belvederi Murri M, Bertelli R, Carozza P, Berardi L, Cantarelli L, Croce E, Antenora F, Curtarello EMA, Simonelli G, Recla E, Girotto B, Grassi L. First-episode psychosis in the Ferrara Mental Health Department: Incidence and clinical course within the first 2 years. Early Interv Psychiatry. 2021 Dec;15(6):1738-1748. doi: 10.1111/eip.13095. Epub 2020 Dec 02. PMID: 33264815.
Copy Download .nbib Format: NLM
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease.

The Journal of antimicrobial chemotherapy

Bouba Y, Armenia D, Forbici F, Bertoli A, Borghi V, Gagliardini R, Vergori A, Cicalini S, Mazzotta V, Malagnino V, Lichtner M, Latini A, Mussini C, Andreoni M, Antinori A, Perno CF, Ceccherini-Silberstein F, Santoro MM.
PMID: 34529797
J Antimicrob Chemother. 2021 Nov 12;76(12):3272-3279. doi: 10.1093/jac/dkab322.

OBJECTIVES: To evaluate HIV-1 tropism in 1382 combined antiretroviral therapy (cART)-experienced patients failing therapy to characterize those with exhausted therapeutic options.METHODS: HIV-1 genotypic tropism was inferred through Geno2Pheno by estimating the false-positive-rate (FPR) values. Cumulative resistance and drug activity...

Cite
Bouba Y, Armenia D, Forbici F, et al. Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. J Antimicrob Chemother. 2021;76(12):3272-3279doi: 10.1093/jac/dkab322.
Bouba, Y., Armenia, D., Forbici, F., Bertoli, A., Borghi, V., Gagliardini, R., Vergori, A., Cicalini, S., Mazzotta, V., Malagnino, V., Lichtner, M., Latini, A., Mussini, C., Andreoni, M., Antinori, A., Perno, C. F., Ceccherini-Silberstein, F., & Santoro, M. M. (2021). Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. The Journal of antimicrobial chemotherapy, 76(12), 3272-3279. https://doi.org/10.1093/jac/dkab322
Bouba, Yagai, et al. "Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease." The Journal of antimicrobial chemotherapy vol. 76,12 (2021): 3272-3279. doi: https://doi.org/10.1093/jac/dkab322
Bouba Y, Armenia D, Forbici F, Bertoli A, Borghi V, Gagliardini R, Vergori A, Cicalini S, Mazzotta V, Malagnino V, Lichtner M, Latini A, Mussini C, Andreoni M, Antinori A, Perno CF, Ceccherini-Silberstein F, Santoro MM. Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. J Antimicrob Chemother. 2021 Nov 12;76(12):3272-3279. doi: 10.1093/jac/dkab322. PMID: 34529797.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 97 entries